Prospect Biosystems' Edge Technology is a major breakthrough, non-denaturing front-end sample fractionation and separation methodology. It comprises a stepwise extraction of a particle mixture using extracting media of increasing densities.

Prospect Biosystems' technology enables scientists involved in the discovery and development of pharmaceutical targets, diagnostics and therapeutics to:

• Rapidly characterize differences between diseased and healthy tissue;
• Significantly enrich low-abundance proteins from their crude extracts;
• Increase the reliability and specificity of downstream analyses;
• Easily identify and evaluate predictive, diagnostic and prognostic biomarkers;
• Facilitate clinical outcome prediction through the use of surrogate biomarkers, and;
• Develop rapid biomarker tests for clinical diagnosis and management.